VerImmune Inc announces the continued growth of its patent portfolio for Virus-inspired Particle (ViP) based Cancer treatment
Received respectively a Notice of Issuance as well as a Notice of Allowance from the USPTO on different US patent family members covering novel virus-inspired compositions and well as traditional virus-like particles.
Washington DC and Singapore-Jan 24th, 2024 VerImmune, Inc., a biotechnology company specializing in Virus-inspired Particle modalities for cancer treatment and other disease areas, proudly announced today the issuance of its third U.S. Patent from the U.S. Patent and Trademark Office (USPTO).
The newly issued patent, U.S. Patent No. 11,858,964 B2, appropriately titled "Virus-inspired Compositions and Methods of Redirecting Pre-existing Immune Responses for the Treatment of Cancer," provides a comprehensive layer of protection and support for VerImmune's ViP proprietary technology platform. This patent includes a novel ViP composition of matter, along with innovative methods for manufacturing and utilizing the technology in cancer treatment. This patent will safeguard the technology platform until at least 2041, which offers an extensive period of exclusivity and protection.
Additionally, VerImmune is also pleased to also announce that the USPTO has issued a notice of allowance for a continuation patent building upon the success of its previously issued patent, U.S. Patent No. 11,285,203, entitled “Chimeric virus-like particles and uses thereof as antigen-specific redirectors of immune responses,” This new additional patent will provide additional claim scope, broadening the protection of VerImmune’s first issued patent family.
Collectively, these latest developments further solidify VerImmune's intellectual property moat at the forefront of cutting-edge cancer treatment technologies.
VerImmune's revolutionary platform is currently focused on redirecting the body's pre-existing T-cell memory against pathogens, effectively harnessing its power to combat cancer. With the potential to target multiple types of cancer, the technology's versatility arises from the near-universal nature of pre-existing responses triggered by childhood vaccines and past infections. As a result, VerImmune's patented technology holds promise for broad applications in cancer treatment, marking a significant stride towards more effective and inclusive solutions.
About VerImmune
VerImmune Inc (www.verimmune.com) is developing a highly innovative Virus-inspired Particle (ViP™) platform technology that has the potential to treat multiple diseases. VerImmune's primary focus lies in the field of Oncology, wherein the ViP technology enables a pioneering first-in-class cancer immunotherapy approach known as Anti-tumor Immune Redirection (AIR). This innovative method harnesses the body's pre-existing immune system, specifically by leveraging the immune memory from past infections or childhood vaccination to combat cancer. By taking a highly orthogonal approach, VerImmune's technology holds immense potential to revolutionize the Immuno-Oncology market, offering new treatment possibilities for patients facing limited options or resistance to current cancer therapies. Beyond Oncology, VerImmune is looking into other areas of high unmet needs via the utilization of ViPs with novel properties and/or payloads that exert highly disruptive mechanisms of action